SCPH
scPharmaceuticals Inc

1,652
Loading...
Loading...
News
all
press releases
MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish
The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion.
Stocktwits·20d ago
News Placeholder
More News
News Placeholder
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside
The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.
Stocktwits·21d ago
News Placeholder
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -13.33% and -2.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Cytek Biosciences, Inc. (CTKB) Beats Q2 Earnings Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of +150.00% and -3.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·2mo ago
News Placeholder
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
Zacks·4mo ago
News Placeholder
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
chainwire·4mo ago
News Placeholder
scPharmaceuticals's Earnings Outlook
read more...
Benzinga·10mo ago
News Placeholder
Buy Rating Affirmed: scPharmaceuticals's Revenue Surge and Product Development Promise
Maxim Group analyst Naz Rahman reiterated a Buy rating on scPharmaceuticals (SCPH Research Report) yesterday and set a price target of $20.00. Na...
TipRanks Financial Blog·1y ago
News Placeholder
Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization
FDA approves scPharmaceuticals' expanded Furoscix indication to include NYHA Class IV heart failure patients. scPharmaceuticals secures $125M non-dilutive financing to repay debt and advance...
Benzinga·1y ago

Latest SCPH News

View

Advertisement. Remove ads.

Advertisement. Remove ads.